By contrast, preliminary data from a second trial of a different anti-IFN agent showed a trend towards a better outcome in the patients with a high IFN signature ( 64 ).
1
—
—
By contrast, preliminary data from a second trial of a different anti-IFN agent showed a trend towards a better outcome in the patients with a high IFN signature ( 64 ).